glutamate carboxypeptidase II
glutamate carboxypeptidase II
Overview
Glutamate carboxypeptidase II (GCPII), also known as prostate-specific membrane antigen (PSMA), is a type II transmembrane glycoprotein that plays a crucial role in the metabolism of glutamate and is highly expressed in prostate cancer tissues. It functions as a carboxypeptidase, hydrolyzing the C-terminal glutamate residues from Peptides and proteins, which is significant in various physiological processes, including neurotransmission and tumor progression. Due to its overexpression in prostate cancer, GCPII has emerged as a prominent target for diagnostic imaging and therapeutic strategies, particularly in the context of metastatic castration-resistant prostate cancer (mCRPC).
Focus of Latest Publications
Recent publications demonstrate that glutamate carboxypeptidase II (PSMA) remains a pivotal target for both diagnostic imaging and therapeutic intervention in metastatic castration-resistant prostate cancer. Radioligand therapy with 177Lu-PSMA-617 continues to establish itself as a transformative treatment modality, with emerging evidence supporting exploration of alternative radionuclides such as 161Tb and 131I-labeled variants to enhance therapeutic efficacy and overcome resistance in patients with progression following initial therapy. Complementary diagnostic imaging strategies, including 68Ga-PSMA-11 and 68Ga-PSMA-based PET-CT, have proven effective in detecting clinically significant disease in patients with high clinical suspicion but equivocal multiparametric MRI findings, reducing unnecessary biopsy procedures. The expanding repertoire of radiopharmaceutical approaches reflects ongoing chemical optimization, with recent reports demonstrating that conjugation of PSMA ligands with lipid-engineered scaffolds or absorption enhancers like SNAC yields improved tumor uptake and retention while maintaining acceptable kidney clearance profiles.
Combination therapeutic strategies incorporating PSMA-targeted agents are gaining traction, with studies evaluating radioligand therapy combined with androgen receptor pathway inhibitors such as enzalutamide or in concert with novel immune modulation strategies targeting immune tolerance pathways. PSMA-positive circulating tumor cells and extracellular vesicles have emerged as candidate biomarkers associated with treatment response and survival outcomes, enabling liquid biopsy-based patient stratification and real-time monitoring of therapy efficacy. These liquid biopsy approaches reveal that baseline levels of PSMA-positive extracellular vesicle proteins correlate with tumor burden on imaging and serum biomarkers, potentially guiding dosing decisions and identifying patients at higher risk of progression.
Beyond prostate cancer, PSMA-targeted radiopharmaceutical therapy is being investigated in clear cell renal cell carcinoma, where PSMA expression in tumor neovasculature offers a tractable therapeutic target for patients whose disease has progressed after immune checkpoint inhibitor and tyrosine kinase inhibitor therapy. Emerging diagnostic innovations include wash-free digital plasmonic assays capable of detecting PSMA-positive extracellular vesicles in plasma within one hour and electrochemical aptasensors enabling urinary PSMA detection with high sensitivity, positioning PSMA as a non-invasive diagnostic biomarker complementary to conventional imaging modalities. Collectively, these advances underscore PSMA's evolving role in precision oncology, with integrated diagnostic imaging, biomarker-driven patient selection, and rationally engineered radioligand designs enhancing both patient outcomes and therapeutic feasibility across multiple cancer types.